These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 32712333)

  • 21. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study.
    Campochiaro C; Della-Torre E; Cavalli G; De Luca G; Ripa M; Boffini N; Tomelleri A; Baldissera E; Rovere-Querini P; Ruggeri A; Monti G; De Cobelli F; Zangrillo A; Tresoldi M; Castagna A; Dagna L;
    Eur J Intern Med; 2020 Jun; 76():43-49. PubMed ID: 32482597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Convalescent plasma therapy for COVID-19: a tried-and-true old strategy?
    Xi Y
    Signal Transduct Target Ther; 2020 Sep; 5(1):203. PubMed ID: 32934211
    [No Abstract]   [Full Text] [Related]  

  • 23. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial.
    Soin AS; Kumar K; Choudhary NS; Sharma P; Mehta Y; Kataria S; Govil D; Deswal V; Chaudhry D; Singh PK; Gupta A; Agarwal V; Kumar S; Sangle SA; Chawla R; Narreddy S; Pandit R; Mishra V; Goel M; Ramanan AV
    Lancet Respir Med; 2021 May; 9(5):511-521. PubMed ID: 33676589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.
    Moutsopoulos HM
    Ann Rheum Dis; 2020 Sep; 79(9):1253-1254. PubMed ID: 32345616
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.
    Morena V; Milazzo L; Oreni L; Bestetti G; Fossali T; Bassoli C; Torre A; Cossu MV; Minari C; Ballone E; Perotti A; Mileto D; Niero F; Merli S; Foschi A; Vimercati S; Rizzardini G; Sollima S; Bradanini L; Galimberti L; Colombo R; Micheli V; Negri C; Ridolfo AL; Meroni L; Galli M; Antinori S; Corbellino M
    Eur J Intern Med; 2020 Jun; 76():36-42. PubMed ID: 32448770
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report.
    Radbel J; Narayanan N; Bhatt PJ
    Chest; 2020 Jul; 158(1):e15-e19. PubMed ID: 32343968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.
    Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA
    Int Immunopharmacol; 2020 Nov; 88():106926. PubMed ID: 32889236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.
    Ramiro S; Mostard RLM; Magro-Checa C; van Dongen CMP; Dormans T; Buijs J; Gronenschild M; de Kruif MD; van Haren EHJ; van Kraaij T; Leers MPG; Peeters R; Wong DR; Landewé RBM
    Ann Rheum Dis; 2020 Sep; 79(9):1143-1151. PubMed ID: 32719045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China.
    Zhu L; Gong N; Liu B; Lu X; Chen D; Chen S; Shu H; Ma K; Xu X; Guo Z; Lu E; Chen D; Ge Q; Cai J; Jiang J; Wei L; Zhang W; Chen G; Chen Z
    Eur Urol; 2020 Jun; 77(6):748-754. PubMed ID: 32317180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection.
    Callejas Rubio JL; Luna Del Castillo JD; de la Hera Fernández J; Guirao Arrabal E; Colmenero Ruiz M; Ortego Centeno N
    Med Clin (Barc); 2020 Aug; 155(4):159-161. PubMed ID: 32532461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extracorporeal Hemoadsorption: An Option for COVID-19-Associated Cytokine Storm Syndrome.
    Napp LC; Bauersachs J
    Shock; 2020 Nov; 54(5):700-701. PubMed ID: 32453251
    [No Abstract]   [Full Text] [Related]  

  • 33. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
    Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
    Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients.
    Klopfenstein T; Zayet S; Lohse A; Balblanc JC; Badie J; Royer PY; Toko L; Mezher C; Kadiane-Oussou NJ; Bossert M; Bozgan AM; Charpentier A; Roux MF; Contreras R; Mazurier I; Dussert P; Gendrin V; Conrozier T;
    Med Mal Infect; 2020 Aug; 50(5):397-400. PubMed ID: 32387320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
    Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Covid-19: Time for a paradigm change.
    Buonaguro FM; Ascierto PA; Morse GD; Buonaguro L; Puzanov I; Tornesello ML; Bréchot C; Gallo RC
    Rev Med Virol; 2020 Sep; 30(5):e2134. PubMed ID: 32618072
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical benefits of Tocilizumab in COVID-19-related cytokine release syndrome in a patient with end-stage kidney disease on haemodialysis in Australia.
    Stephen S; Park YA; Chrysostomou A
    Nephrology (Carlton); 2020 Nov; 25(11):845-849. PubMed ID: 32776624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.
    Chrousos GP; Meduri GU
    Clin Immunol; 2020 Oct; 219():108550. PubMed ID: 32745524
    [No Abstract]   [Full Text] [Related]  

  • 40. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.
    Tleyjeh IM; Kashour Z; Damlaj M; Riaz M; Tlayjeh H; Altannir M; Altannir Y; Al-Tannir M; Tleyjeh R; Hassett L; Kashour T
    Clin Microbiol Infect; 2021 Feb; 27(2):215-227. PubMed ID: 33161150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.